This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

sparsentan for treating primary IgA nephropathy

Authoring team

Sparsentan is a dual endothelin angiotensin receptor antagonist developed for the treatment of IgA nephropathy (1).

NICE state that (2):

Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a:

  • urine protein excretion of 1.0 g/day or more, or
  • urine protein-to-creatinine ratio (UPCR) of 0.75 g/g or more

Sparsentan should be stopped after 36 weeks if a person's UPCR:

  • is 1.76 g/g or more and
  • has not reduced by 20% or more since starting sparsentan

The NICE committee note that "...clinical trial evidence shows that sparsentan reduces UPCR more than irbesartan. Evidence also suggests that sparsentan is better at maintaining kidney function than irbesartan, but this is uncertain..."

Reference:

  1. Syed YY. Sparsentan: First Approval. Drugs. 2023 Apr;83(6):563-568.
  2. NICE (June 2025). Sparsentan for treating primary IgA nephropathy

 

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.